Elite Pharmaceuticals Inc (ELTP)

[WeeZuhl]

Trends in company stock prices before the first public announcement differ for companies that report positive vs negative trials. On that point, here is some research that found an impact on the p/s following FDA announcements ...

Interesting report. My interpretation of the data is that positive news tends to leak, and a lack of a positive news leak has a smaller, downward effect on a stock. Play by the rules and get whacked for it. It is important to note that this report is not applicable to isradipine, which is a truly unique situation. This will not be an FDA regulatory decision. The research was not sponsored by Elite, and Elite will not be mentioned in association with the research results. I am not sure the market will appreciate the connection between ELTP and STEADYPD-III, at least until it hits an earnings report. Good results will be good for Elite, the old-fashioned way, by selling more product in response to increased demand. I'll take that all day, but I continue to urge for tempered expectations regarding an immediate effect of isradipine news, even great news.


Having said that, your post has me intrigued. I know you have a communication channel with HQ. I seem to remember Nasrat referring to you fondly during a call. So time to 'fess up, N2K. What do you know about the company's intentions for a PR in the event the results are good? Easily justifiable as a material event to try to associate ELTP's isradipine with STEADYPD-III, but very, very sticky territory with the FDA. They tend to frown upon drug companies advocating for an off-label use of any drug. They know it happens all the time, but they do not tolerate companies who push it. Could get the right kind of attention from the market while it gets the wrong kind of attention from FDA.